1 |
李小秋, 李甘地, 高子芬, 等. 中国淋巴瘤亚型分布: 国内多中心性病例10002例分析[J]. 诊断学理论与实践, 2012, 11(2): 111-115.
|
2 |
王艳芳, 克晓燕. T细胞淋巴瘤的研究进展[J]. 白血病·淋巴瘤, 2008, 17(3): 234-237.
|
3 |
Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy[J]. Blood, 2019, 133(2): 137-146.
|
4 |
Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group[J]. Eur J Cancer, 2013, 49(16): 3486-3496.
|
5 |
Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial[J]. JAMA, 2014, 312(23): 2521-2530.
|
6 |
中华医学会血液学分会, 中国抗癌协会淋巴瘤专业委员会, 中华医学会肝病学分会. 中国淋巴瘤合并HBV感染患者管理专家共识[J]. 中华血液学杂志, 2013, 34(11): 988-993.
|
7 |
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019, 27(12): 938-961.
|
8 |
Ifuku H, Kusumoto S, Tanaka Y, et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab[J]. Hepatol Res, 2015, 45(13): 1363-1367.
|
9 |
Nakano N, Kusumoto S, Tanaka Y, et al. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab[J]. Hepatol Res, 2014, 44(3): 354-357.
|
10 |
Totani H, Kusumoto S, Ishida T, et al. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy[J]. Int J Hematol, 2015, 101(4): 398-404.
|
11 |
Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients[J]. Ann Hematol, 2010, 89(3): 255-262.
|
12 |
Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors[J]. J Med Virol, 2000, 62(3): 299-307.
|
13 |
Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma[J]. Hepatology, 2003, 37(6): 1320-1328.
|
14 |
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6): 1297-1309.
|
15 |
Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy[J]. World J Clin Cases, 2021, 9(21): 5769-5781.
|
16 |
Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study[J]. Hepatology, 2014, 59(6): 2092-2100.
|
17 |
朱倩, 韩悦. 外周T细胞淋巴瘤的研究进展[J/OL].中华临床医师杂志(电子版), 2013, 7(6): 2638-2640.
|
18 |
Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study[J]. J Clin Oncol, 2014, 32(33): 3736-3743.
|
19 |
Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B[J]. J Clin Oncol, 2013, 31(22): 2765-2772.
|
20 |
Khanam A, Ghosh A, Chua JV, et al. Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways[J]. J Transl Med, 2023, 21(1): 271.
|